RA'ANANA, Israel, April 3,
2024 /PRNewswire/ -- Inspira™ Technologies
OXY B.H.N. Ltd. (NASDAQ: IINN) (NASDAQ: IINNW) (the
"Company" or "Inspira"), a breakthrough medical technology
company, is delighted to announce the commencement of a program to
explore the applicable use of the INSPIRA™ ART100 Device for an
artificial womb for neonates in need of vital respiratory
support.
Inspira aims to explore how this potential additional
application of the INSPIRA ART100 device to provide neonates with
vital respiratory support could replace the currently used
mechanical ventilators. The high pressure and complications
associated with mechanical ventilation can cause harsh and
long-term negative effects on neonates who require respiratory life
support during the early and critical stages of their neonatal
development. The potential additional application targets
prematurely born neonates with underdeveloped respiratory systems
and neonates with life-threatening disorders such as meconium
aspiration syndrome, the disorder that results in neonates
experiencing difficulty in breathing as a result of meconium in the
lungs, and congenital diaphragmatic hernia, where the muscle that
bisects the chest from the abdomen fails to close.
"Inspira is dedicated to pushing the boundaries of medical
technology to save and improve lives," remarked Dagi Ben-Noon,
CEO of Inspira Technologies. "This initiative marks another
step in the journey towards providing safer alternatives to
mechanical ventilation. Together, we are targeting to reshape the
landscape of acute neonatal care."
Inspira Technologies OXY B.H.N. Ltd.
Inspira™ Technologies is an innovative medical technology
company in the respiratory treatment arena. The Company has
developed a breakthrough Augmented Respiration Technology (INSPIRA
ART), designed to rebalance patient oxygen saturation levels. This
technology potentially allows patients to remain awake during
treatment while reducing the need for highly invasive, risky, and
costly mechanical ventilation systems that require intubation and
medically induced coma. The Company's products have not yet been
tested or used in humans and has not been approved by any
regulatory entity.
For more information, please visit our corporate
website: https://inspira-technologies.com
Forward-Looking Statement Disclaimer
This press release contains express or implied forward-looking
statements pursuant to U.S. Federal securities laws. These
forward-looking statements and their implications are based on the
current expectations of the management of the Company only and are
subject to a number of factors and uncertainties that could cause
actual results to differ materially from those described in the
forward-looking statements. For example, the Company is using
forward-looking statements when it discusses the aims of the
research and development into various potential uses of the INSPIRA
ART100 device and the Company's aim to reshape the landscape of
acute neonatal care. These forward-looking statements and their
implications are based solely on the current expectations of the
Company's management and are subject to a number of factors and
uncertainties that could cause actual results to differ materially
from those described in the forward-looking statements. Except as
otherwise required by law, the Company undertakes no obligation to
publicly release any revisions to these forward-looking statements
to reflect events or circumstances after the date hereof or to
reflect the occurrence of unanticipated events. More detailed
information about the risks and uncertainties affecting the Company
is contained under the heading "Risk Factors" in the Company's
annual report on Form 20-F for the fiscal year ended December 31, 2023 filed with the U.S. Securities
and Exchange Commission (the "SEC"), which is available on the
SEC's website, http://www.sec.gov
For more details:
Public Relations Manager
Adi Shmueli
Inspira Technologies
info@inspirao2.com
+972-9-9664485
Copyright © 2018-2024 Inspira Technologies OXY B.H.N. LTD., All
rights reserved.
Logo -
https://mma.prnewswire.com/media/1668495/Inspira_Technologies_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/inspira-announces-program-to-pioneer-the-applicable-use-of-the-inspira-art100-device-for-an-artificial-womb-302107173.html
SOURCE Inspira Technologies
